Kamil Oskar Kozub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kamil Oskar Kozub has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Cudnoch-Jędrzejewska
Laboratory of Centre for Preclinical Research, Chair and Department of Experimental and Clinical Physiology, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland
1 shared publication - Jan Jankowski
1st Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland
1 shared publication - Katarzyna Camlet
District Hospital in Zakopane, Kamieniec 10, 34-500 Zakopane, Poland
1 shared publication - Klaudia Kleibert
Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, 02-091 Warsaw, Poland
1 shared publication - Marcin Kleibert
Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 14 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 9921
The Role of Programmed Types of Cell Death in Pathogenesis of Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a condition that develops in the course of many diseases and conditions, and its pathophysiology is still not well understood, but the involvement of programmed types of cell death in the development of this type of heart failure is becoming increasingly certain. In addition, drugs already widely used in clinical practice, with a good safety profile and efficacy demonstrated in large-group clinical trials, seem to be exerting their beneficial effects on cardiovascular health. Perhaps new drugs that reduce the susceptibility of cells to programmed types of cell death are under investigation and may improve the prognosis of patients with HFpEF. In this article, we summarize the current knowledge about the pathogenesis of HFpEF and the role of programmed types of cell death in its development. Additionally, we have described the future directions of research that may lead to the improvement of a patient’s prognosis and potential treatment.
- 14 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 9921
Open AccessThe Role of Programmed Types of Cell Death in Pathogenesis of Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a condition that develops in the course of many diseases and conditions, and its pathophysiology is still not well understood, but the involvement of programmed types of cell death in the development of this type of heart failure is becoming increasingly certain. In addition, drugs already widely used in clinical practice, with a good safety profile and efficacy demonstrated in large-group clinical trials, seem to be exerting their beneficial effects on cardiovascular health. Perhaps new drugs that reduce the susceptibility of cells to programmed types of cell death are under investigation and may improve the prognosis of patients with HFpEF. In this article, we summarize the current knowledge about the pathogenesis of HFpEF and the role of programmed types of cell death in its development. Additionally, we have described the future directions of research that may lead to the improvement of a patient’s prognosis and potential treatment.